Status:
UNKNOWN
CRC Post-surgical Assessment and Recurrence Monitoring
Lead Sponsor:
BioChain (Beijing) Science and Technology, Inc.
Collaborating Sponsors:
Chinese PLA General Hospital
First Hospitals affiliated to the China PLA General Hospital
Conditions:
Colorectal Cancer
Eligibility:
All Genders
30-80 years
Brief Summary
The surgical therapeutic effect of stage II-IV CRC patients will be assessed by the plasma mSEPT9 assay, and patients will be followed up by the same assay for recurrence monitoring.
Detailed Description
Assessment of surgical therapeutic effect of colorectal cancer (CRC) relies on computer tomography (CT) and serum CEA test. CT cannot be used frequently to monitor the instant change of lesions, while...
Eligibility Criteria
Inclusion
- stage II-IV CRC patients planning to perform surgery
Exclusion
- stage 0-I CRC patients, patients with history of CRC or other cancers, patients not suitable for surgery, pregnant women, patients younger than 30 or older than 80.
Key Trial Info
Start Date :
January 1 2016
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2017
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT03334890
Start Date
January 1 2016
End Date
December 31 2017
Last Update
November 7 2017
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
The Chinese PLA 302th hospital
Beijing, China
2
The Chinese PLA 309th hospital
Beijing, China
3
The Chinese PLA general hospital
Beijing, China
4
The first affiliated hospital of the Chinese PLA general hospital
Beijing, China